目的 系统评价醒脑静注射液辅助治疗脑卒中后继发性癫痫。方法 检索PubMed、Embase以及中国知网数据库、万方数据库、维普数据库中关于醒脑静注射液辅助治疗脑卒中后继发性癫痫的临床随机对照试验，按照Cochrane协作网的系统评价要求，制定纳入及排除标准，按照改良的Jadad量表对文献进行质量评价，绘制基本信息表，提取数据，使用RevMan5.3软件进行Meta分析，绘制偏倚风险图、森林图及漏斗图。结果 共有20项研究被纳入,总病例数1 714例。Meta分析结果提示醒脑静注射液辅助治疗脑卒中后继发性癫痫在提高总有效率、减少脑电图痫样放电数、痫样放电累及的导联数以及改善相关生活质量方面均优于单纯服用抗癫痫药物治疗的对照组患者。不良反应方面，观察组癫痫患者的神经系统和消化系统不良反应均明显低于对照组患者，而两组的皮肤不良反应无明显差异。结论 醒脑静注射液辅助治疗脑卒中后继发性癫痫安全有效，但因研究方法质量学的限制，有待于高质量、大样本的临床随机试验提供循证依据。

Objective To systematically evaluate Xingnaojing injection in the treatment of secondary epilepsy after stroke. Methods The clinical randomized controlled trials of PubMed, Embase, and China Knowledge Network database, Wanfang database and Weipu database on the treatment of secondary epilepsy after stroke with Xingnaojing injection were developed. According to the systematic evaluation requirements of Cochrane Collaboration, the inclusion and exclusion criteria, quality evaluation of the literature was performed according to the improved Jadad scale, basic information table, data extraction. Meta-analysis was conducted by using RevMan5.3 software, mapping risk map, forest map and funnel plot. Results A total of 20 studies were included, with a total of 1714 cases. Meta-analysis results suggest that Xingnaojing injection was superior to simple treatment for secondary epilepsy after stroke in improving total effective rate, reducing the number of EEG epileptic discharges, the number of leads involved in epileptic form discharge, and improving related quality of life. A control group of patients were taking anti-epileptic drugs. In terms of adverse reactions, the neurological and digestive system adverse reactions of the epilepsy patients in the observation group were significantly lower than those in the control group, but there was no significant difference in skin adverse reactions between the 2 groups. Conclusion Xingnaojing injection is safe and effective in the treatment of secondary epilepsy after stroke. However, due to the limitations of the quality of the research methods, it is necessary to provide evidence-based evidence for high-quality, large-sample clinical randomized trials.

R289.5